Overview

Same-Day Treatment With Genvoya vs. EFV/TDF/3TC

Status:
Withdrawn
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Randomized, open-label study comparing Elvitegravir-Cobicistat-Tenofovir Alafenamide-Emtricitabine (Genvoya) vs. Efavirenz-Tenofovir Disoproxil Fumarate-Lamivudine (EFV-TDF-3TC) in patients starting ART on the day of HIV diagnosis.
Phase:
N/A
Details
Lead Sponsor:
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
Collaborators:
Analysis Group, Inc.
Brigham and Women's Hospital
Gilead Sciences
Weill Medical College of Cornell University
Treatments:
Cobicistat
Efavirenz
Elvitegravir
Tenofovir